FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040709804> ?p ?o ?g. }

• W2040709804 endingPage "4140" @default.
• W2040709804 startingPage "4129" @default.
• W2040709804 abstract "Tamoxifen (Tam) treatment is a first-line endocrine therapy for estrogen receptor-α-positive breast cancer patients. Unfortunately, resistance frequently occurs and is often related with overexpression of the membrane tyrosine kinase receptor HER2. This is the rationale behind combined treatments with endocrine therapy and novel inhibitors that reduce HER2 expression and signaling and thus inhibit Tam-resistant breast cancer cell growth. In this study, we show that activation of farnesoid X receptor (FXR), by the primary bile acid chenodeoxycholic acid (CDCA) or the synthetic agonist GW4064, inhibited growth of Tam-resistant breast cancer cells (termed MCF-7 TR1), which was used as an in vitro model of acquired Tam resistance. Our results demonstrate that CDCA treatment significantly reduced both anchorage-dependent and anchorage-independent epidermal growth factor (EGF)-induced growth in MCF-7 TR1 cells. Furthermore, results from western blot analysis and real-time reverse transcription–PCR revealed that CDCA treatment reduced HER2 expression and inhibited EGF-mediated HER2 and p42/44 mitogen-activated protein kinase (MAPK) phosphorylation in these Tam-resistant breast cancer cells. Transient transfection experiments, using a vector containing the human HER2 promoter region, showed that CDCA treatment downregulated basal HER2 promoter activity. This occurred through an inhibition of nuclear factor-κB transcription factor binding to its specific responsive element located in the HER2 promoter region as revealed by mutagenesis studies, electrophoretic mobility shift assay and chromatin immunoprecipitation analysis. Collectively, these data suggest that FXR ligand-dependent activity, blocking HER2/MAPK signaling, may overcome anti-estrogen resistance in human breast cancer cells and could represent a new therapeutic tool to treat breast cancer patients that develop resistance." @default.
• W2040709804 created "2016-06-24" @default.
• W2040709804 creator A5013221500 @default.
• W2040709804 creator A5020724674 @default.
• W2040709804 creator A5022037891 @default.
• W2040709804 creator A5029676025 @default.
• W2040709804 creator A5046031758 @default.
• W2040709804 creator A5054255756 @default.
• W2040709804 creator A5054597220 @default.
• W2040709804 creator A5054714711 @default.
• W2040709804 creator A5065841224 @default.
• W2040709804 creator A5089369776 @default.
• W2040709804 date "2011-04-18" @default.
• W2040709804 modified "2023-10-18" @default.
• W2040709804 title "Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression" @default.
• W2040709804 cites W1541544453 @default.
• W2040709804 cites W1639582946 @default.
• W2040709804 cites W1898692666 @default.
• W2040709804 cites W1966052494 @default.
• W2040709804 cites W1967244419 @default.
• W2040709804 cites W1976621716 @default.
• W2040709804 cites W1977254575 @default.
• W2040709804 cites W2007233147 @default.
• W2040709804 cites W2016569614 @default.
• W2040709804 cites W2022102157 @default.
• W2040709804 cites W2025005089 @default.
• W2040709804 cites W2025356826 @default.
• W2040709804 cites W2028072190 @default.
• W2040709804 cites W2036752075 @default.
• W2040709804 cites W2042473840 @default.
• W2040709804 cites W2053581007 @default.
• W2040709804 cites W2054906038 @default.
• W2040709804 cites W2070417113 @default.
• W2040709804 cites W2074545460 @default.
• W2040709804 cites W2081928176 @default.
• W2040709804 cites W2085962925 @default.
• W2040709804 cites W2090378553 @default.
• W2040709804 cites W2094646101 @default.
• W2040709804 cites W2095156669 @default.
• W2040709804 cites W2109388713 @default.
• W2040709804 cites W2109423875 @default.
• W2040709804 cites W2112252566 @default.
• W2040709804 cites W2112986537 @default.
• W2040709804 cites W2114974083 @default.
• W2040709804 cites W2121409164 @default.
• W2040709804 cites W2125524268 @default.
• W2040709804 cites W2125785648 @default.
• W2040709804 cites W2127727592 @default.
• W2040709804 cites W2131655174 @default.
• W2040709804 cites W2132950000 @default.
• W2040709804 cites W2136118363 @default.
• W2040709804 cites W2137355132 @default.
• W2040709804 cites W2138911924 @default.
• W2040709804 cites W2139995230 @default.
• W2040709804 cites W2141232624 @default.
• W2040709804 cites W2141647078 @default.
• W2040709804 cites W2147466223 @default.
• W2040709804 cites W2148320836 @default.
• W2040709804 cites W2155391879 @default.
• W2040709804 cites W2156034409 @default.
• W2040709804 cites W2164020327 @default.
• W2040709804 cites W2171398834 @default.
• W2040709804 cites W2318605753 @default.
• W2040709804 cites W4249387963 @default.
• W2040709804 doi "https://doi.org/10.1038/onc.2011.124" @default.
• W2040709804 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4482257" @default.
• W2040709804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21499302" @default.
• W2040709804 hasPublicationYear "2011" @default.
• W2040709804 type Work @default.
• W2040709804 sameAs 2040709804 @default.
• W2040709804 citedByCount "53" @default.
• W2040709804 countsByYear W20407098042012 @default.
• W2040709804 countsByYear W20407098042013 @default.
• W2040709804 countsByYear W20407098042014 @default.
• W2040709804 countsByYear W20407098042015 @default.
• W2040709804 countsByYear W20407098042016 @default.
• W2040709804 countsByYear W20407098042017 @default.
• W2040709804 countsByYear W20407098042018 @default.
• W2040709804 countsByYear W20407098042019 @default.
• W2040709804 countsByYear W20407098042020 @default.
• W2040709804 countsByYear W20407098042021 @default.
• W2040709804 countsByYear W20407098042022 @default.
• W2040709804 crossrefType "journal-article" @default.
• W2040709804 hasAuthorship W2040709804A5013221500 @default.
• W2040709804 hasAuthorship W2040709804A5020724674 @default.
• W2040709804 hasAuthorship W2040709804A5022037891 @default.
• W2040709804 hasAuthorship W2040709804A5029676025 @default.
• W2040709804 hasAuthorship W2040709804A5046031758 @default.
• W2040709804 hasAuthorship W2040709804A5054255756 @default.
• W2040709804 hasAuthorship W2040709804A5054597220 @default.
• W2040709804 hasAuthorship W2040709804A5054714711 @default.
• W2040709804 hasAuthorship W2040709804A5065841224 @default.
• W2040709804 hasAuthorship W2040709804A5089369776 @default.
• W2040709804 hasBestOaLocation W20407098041 @default.
• W2040709804 hasConcept C104317684 @default.
• W2040709804 hasConcept C121608353 @default.
• W2040709804 hasConcept C126322002 @default.
• W2040709804 hasConcept C134018914 @default.

• next